Navigation Links
Pharmacyclics Reports Recent Developments From Clinical Studies of its Btk Inhibitor PCI-32765
Date:6/6/2011

re approximately 475,000 people in the United States alone living with NHL (active disease or in remission).

About Pharmacyclics
Pharmacyclics® is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative small-molecule drugs for the treatment of cancer and immune mediated diseases. Our mission and goal is to build a viable biopharmaceutical company that designs, develops and commercializes novel therapies intended to improve quality of life, increase duration of life and resolve serious unmet medial healthcare needs; and to identify promising product candidates based on scientific development expertise, develop our products in a rapid, cost-efficient manner and pursue commercialization and/or development partners when and where appropriate.

Presently, Pharmacyclics has four product candidates in clinical development and several preclinical molecules in lead optimization. We are committed to high standards of ethics, scientific rigor, and operational efficiency as we move each of these programs to viable commercialization.

The Company is headquartered in Sunnyvale, California and is listed on NASDAQ under the symbol PCYC. To learn more about how Pharmacyclics advances science to improve human healthcare visit us at http://www.pharmacyclics.com.

NOTE: This announcement may contain forward-looking statements made in reliance upon the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements regarding our expectations and beliefs regarding our future results or performance. Because these statements apply to future events, they are subject to risks and uncertainties. When used in this announcement, the words "anticipate", "believe", "estimate", "expect", "expectation", "should", "would", "project", "plan", "predict", "intend" a
'/>"/>

SOURCE Pharmacyclics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Pharmacyclics Announces Data and Publication Characterizing Highly-Selective HDAC Inhibitor
2. Pharmacyclics Announces Preclinical Results Supporting Development of Its Novel Btk Inhibitor in Immune Mediated Diseases
3. Pharmacyclics Reports Multiple Presentations at AACR on Its HDAC and Selective HDAC Inhibitors
4. Pharmacyclics Novel Factor VIIa Inhibitor Demonstrates Potential Inhibition of Tumor Growth in Multiple Types of Cancer
5. Pharmacyclics Novel Btk Inhibitor Shows Efficacy in Preclinical Models of Rheumatoid Arthritis and Lymphoma
6. Pharmacyclics Announces Completion of Phase 1 Clinical Trial of Factor VIIa Inhibitor PCI-27483
7. Pharmacyclics, Inc. Announces Closing of a Private Financing With the Principals of Pacific Biopharma Group, Ltd.
8. Pharmacyclics Initiates Phase 1 Clinical Trial of Novel Oral Btk Inhibitor for Refractory B-cell Non-Hodgkins Lymphoma
9. Pharmacyclics announces Global Strategic Alliance with Les Laboratoires Servier
10. Pharmacyclics to Present at Merriman Curhan Fords Investor Summit 2009
11. Pharmacyclics Announces Poster Presentations and Clinical Update at the 51st Annual Meeting of the American Society of Hematology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)... July 22, 2014 WuXi PharmaTech (Cayman) Inc. (NYSE: ... device R&D outsourcing company with operations in China ... today announced that it will release financial results for the ... closes on Wednesday, August 13, 2014 (which will be Thursday ... be available on the investor relations section of the Company,s ...
(Date:7/22/2014)... EASTON, Mass. , July 22, 2014 ... or the "Company") and Parabase Genomics ("Parabase"), ... entered into a strategic research and development ... the collaboration, PBI will develop a front-end, ... molecular diagnostics and newborn confirmatory testing process. ...
(Date:7/22/2014)... New York , July 22, ... Neue Partnerschaft für umfassenden Schutz von ... in Österreich    Equashield ... von geschlossenen Transfersystemen (Closed System Transfer Devices, CSTDs) für ... , einen Vertriebshändler und Hersteller von ...
Breaking Medicine Technology:WuXi PharmaTech Schedules Second-Quarter 2014 Earnings Release 2Pressure BioSciences to Develop Front-end Sample Preparation for Parabase Genomics' Targeted Next Generation Sequencing Testing Platform 2Pressure BioSciences to Develop Front-end Sample Preparation for Parabase Genomics' Targeted Next Generation Sequencing Testing Platform 3Pressure BioSciences to Develop Front-end Sample Preparation for Parabase Genomics' Targeted Next Generation Sequencing Testing Platform 4Equashield ernennt Medikus zu seinem exklusiven österreichischen Vertriebspartner für seine geschlossenen Arzneimitteltransfersysteme 2
... 1, 2011 Health Diagnostic Laboratory Inc. (HDL, ... to develop a novel laboratory developed test with ... diagnostic test and surgical therapy solutions for the ... coronary heart disease (CHD) and stroke are responsible ...
... Radiation Therapy Services Holdings, Inc. ("Radiation Therapy") announced ... International, Inc., has acquired Medical Developers, LLC ("MDLLC"), ... treatment facilities in Latin America. The ... of $47.5 million in cash, $16.25 million in ...
Cached Medicine Technology:Health Diagnostic Laboratory, Inc. (HDL, Inc.) Partners With Gamma Therapeutics to Offer Breakthrough Diagnostic Assay for Heart Attack and Stroke Risk 2Health Diagnostic Laboratory, Inc. (HDL, Inc.) Partners With Gamma Therapeutics to Offer Breakthrough Diagnostic Assay for Heart Attack and Stroke Risk 3Radiation Therapy Services Holdings, Inc. Acquires Medical Developers, LLC 2Radiation Therapy Services Holdings, Inc. Acquires Medical Developers, LLC 3
(Date:7/22/2014)... 2014 Legislation backed by the ... Local Pharmacies Act of 2014”) championing so-called “any ... undermine the availability of lower cost preferred pharmacy ... over the next 10 years, according to new ... Pharmaceutical Care Management Association (PCMA). , The drugstore ...
(Date:7/22/2014)... guidelines on cholesterol treatment and cardiovascular risk assessment state ... dying from atherosclerotic cardiovascular disease or of having a ... similar risk profile (based on age, smoking history, and ... finding for when and how aggressively to treat high ... of Men,s Health , a peer-reviewed publication from Mary ...
(Date:7/22/2014)... 22, 2014 The Pennsylvania judge ... ) in the Philadelphia Court of Common ... damages in cases alleging the medication caused plaintiffs ... LLP reports. In an Order dated July 18, ... request to certify the matter for an immediate ...
(Date:7/22/2014)... 2014 (HealthDay News) -- One of the largest studies ... disorder has uncovered 83 new sites on chromosomes that ... made by an international team of researchers, now bring ... the disorder to 108. Although these schizophrenia-associated ... test to predict who will or will not develop ...
(Date:7/22/2014)... Bayonne, NJ (PRWEB) July 22, 2014 CarePoint ... been recently elected as the President of the medical staff ... Dr. Levine will serve as President, as voted on by ... interests of the medical staff in relation to the administration ... the needs of physicians and to work to make the ...
Breaking Medicine News(10 mins):Health News:PCMA: New Study Finds H.R. 4577 to Cost $21 Billion Over 10 Years 2Health News:Risperdal Lawsuit News: Pennsylvania Judge Won’t Reconsider Denial of Punitive Damages for Risperdal Gynecomastia Plaintiffs, Bernstein Liebhard LLP Reports 2Health News:Risperdal Lawsuit News: Pennsylvania Judge Won’t Reconsider Denial of Punitive Damages for Risperdal Gynecomastia Plaintiffs, Bernstein Liebhard LLP Reports 3Health News:Risperdal Lawsuit News: Pennsylvania Judge Won’t Reconsider Denial of Punitive Damages for Risperdal Gynecomastia Plaintiffs, Bernstein Liebhard LLP Reports 4Health News:Gene Discoveries Could Shed New Light on Schizophrenia 2Health News:Dr. Howard Levine Elected President of the Medical Staff at Bayonne Medical Center 2
... good judges of affordability, but a new study reveals that ... you think about a larger pool of resources (such as ... your wallet). Through a series of four experiments, researchers ... time. Counting calories" Youre more likely to eat that slice ...
... from the University of California San Francisco has identified ... woman is likely to develop subsequent invasive cancer after ... cancer. The research, published by Cell Press in the ... can be used to determine whether a woman should ...
... GREEN BAY, Wis., Nov. 12 Shopko announced ... position of President and Chief,Merchandising Officer. Jones will ... marketing activities of the regional mass retailer. ... roles in the,department store sector, mid-tier chain stores ...
... Va., Nov. 12 Conservationists and scientists,from around ... and Research Symposium, in Orlando, Florida. The Symposium ... Bailey Center for Elephant,Conservation(R) and the International Elephant ... two day global Conference on Elephant,Tuberculosis Research. The ...
... Health releases nationwide eValue8,findings, SCOTTSDALE, Ariz., ... report of health plan performance released today ... (NBCH), health plans could do a,better job ... enabling,improvements in patient safety, care coordination, consumer ...
... Hazelden Foundation offers Barry McMillen - Nicotine Cessation Expert and ... ... Nov. 12 Using tobacco isn,t just a,habit; it,s an addiction. ... for over 50 years. The same principles,of the Hazelden treatment experience ...
Cached Medicine News:Health News:Big ticket: You'll spend more thinking about your bank account than about your wallet 2Health News:Biomarkers predict risk for invasive breast cancer years before the tumor develops 2Health News:Conference on Elephant Tuberculosis Research Establishes Action Plan at International Symposium on Elephant Conservation 2Health News:Conference on Elephant Tuberculosis Research Establishes Action Plan at International Symposium on Elephant Conservation 3Health News:Conference on Elephant Tuberculosis Research Establishes Action Plan at International Symposium on Elephant Conservation 4Health News:National Survey Finds Employers are Challenging Health Plans to Better Use Resources to Prevent Illness and Improve Patient Safety 2Health News:National Survey Finds Employers are Challenging Health Plans to Better Use Resources to Prevent Illness and Improve Patient Safety 3Health News:National Survey Finds Employers are Challenging Health Plans to Better Use Resources to Prevent Illness and Improve Patient Safety 4Health News:Quit Smoking Tips For The Great American Smokeout Day - November 15 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: